These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28236105)

  • 1. Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach.
    Morello G; Spampinato AG; Conforti FL; D'Agata V; Cavallaro S
    J Mol Neurosci; 2017 Apr; 61(4):563-580. PubMed ID: 28236105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS.
    Haenggeli C; Julien JP; Mosley RL; Perez N; Dhar A; Gendelman HE; Rothstein JD
    Neurobiol Dis; 2007 Apr; 26(1):146-52. PubMed ID: 17276077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
    Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
    Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis.
    Nardo G; Iennaco R; Fusi N; Heath PR; Marino M; Trolese MC; Ferraiuolo L; Lawrence N; Shaw PJ; Bendotti C
    Brain; 2013 Nov; 136(Pt 11):3305-32. PubMed ID: 24065725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy.
    Morello G; Cavallaro S
    Future Med Chem; 2015; 7(10):1335-59. PubMed ID: 26144267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
    Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
    J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor neuron disease: a chemical perspective.
    Wood LK; Langford SJ
    J Med Chem; 2014 Aug; 57(15):6316-31. PubMed ID: 24694032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
    Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis.
    Lederer CW; Torrisi A; Pantelidou M; Santama N; Cavallaro S
    BMC Genomics; 2007 Jan; 8():26. PubMed ID: 17244347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein nonmetastatic melanoma protein B ameliorates skeletal muscle lesions in a SOD1G93A mouse model of amyotrophic lateral sclerosis.
    Nagahara Y; Shimazawa M; Tanaka H; Ono Y; Noda Y; Ohuchi K; Tsuruma K; Katsuno M; Sobue G; Hara H
    J Neurosci Res; 2015 Oct; 93(10):1552-66. PubMed ID: 26140698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis.
    Kim J; Kim TY; Cho KS; Kim HN; Koh JY
    Neurobiol Dis; 2013 Nov; 59():80-5. PubMed ID: 23891729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neuroprotective drugs on gene expression in G93A/SOD1 mice.
    Ignacio S; Moore DH; Smith AP; Lee NM
    Ann N Y Acad Sci; 2005 Aug; 1053():121-36. PubMed ID: 16179515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis.
    Feng X; Peng Y; Liu M; Cui L
    Neuropharmacology; 2012 Feb; 62(2):1004-10. PubMed ID: 22056419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
    Petri S; Kiaei M; Kipiani K; Chen J; Calingasan NY; Crow JP; Beal MF
    Neurobiol Dis; 2006 Apr; 22(1):40-9. PubMed ID: 16289867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model.
    Li Y; Guo Y; Wang X; Yu X; Duan W; Hong K; Wang J; Han H; Li C
    Neuroscience; 2015 Jul; 298():12-25. PubMed ID: 25841320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive impairment of CaV1.1 function in the skeletal muscle of mice expressing a mutant type 1 Cu/Zn superoxide dismutase (G93A) linked to amyotrophic lateral sclerosis.
    Beqollari D; Romberg CF; Dobrowolny G; Martini M; Voss AA; Musarò A; Bannister RA
    Skelet Muscle; 2016; 6():24. PubMed ID: 27340545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
    Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
    J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
    Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
    Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.
    Glajch KE; Ferraiuolo L; Mueller KA; Stopford MJ; Prabhkar V; Gravanis A; Shaw PJ; Sadri-Vakili G
    PLoS One; 2016; 11(10):e0164103. PubMed ID: 27716798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models.
    Audet JN; Soucy G; Julien JP
    Neuroscience; 2012 May; 209():136-43. PubMed ID: 22230045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.